Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
huangjingjiannao prescription
- Development stage
- Phase 1
- Lead developer
- Guang'anmen Hospital
- Administration
- Oral
01
Overview
Huangjingjiannao prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by Guang'anmen Hospital for the treatment of vascular mild cognitive impairment (vMCI). The formula is primarily composed of *Polygonatum sibiricum* (Huangjing) and other traditional herbs intended to tonify the kidney and invigorate the brain. It is currently being evaluated in clinical trials (e.g., ChiCTR2200061393) to assess its efficacy compared to donepezil, focusing on cognitive improvement, daily functioning, and changes in brain connectivity and structure as visualized by multimodality MRI.
- Other names
- Huangjing Jiannao formulaHuangjing Jiannao Fanghuangjingjiannao prescription
Beyond the preview
Go deeper on huangjingjiannao prescription.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on huangjingjiannao prescription.